Autolus Announces Pricing of Underwritten Offering
February 08, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Announces Pricing of Underwritten Offering
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
February 08, 2024 05:45 ET
|
Autolus Therapeutics plc; BioNTech SE
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
Global CAR-T Cell Therapy Market Report 2024-2034: Accelerated Growth Fueled by Intensive R&D, Growing Medical Recognition, and Fast Track Designation Regulatory Approvals
January 24, 2024 14:23 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global CAR-T Cell Therapy Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. With the...
Global CAR T-Cell Therapy Research Report 2023: Market Poised for Substantial Growth by 2030, Driven by Advancements in Cancer Treatment and Increasing Incidence Rates
January 24, 2024 04:13 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global CAR T-Cell Therapy Market 2030 by Drug type, Indication, Target Antigen, End-user and Region - Partner & Customer Ecosystem Competitive...
Autolus Therapeutics announces publication in ACS Chemical Biology
January 23, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics announces publication in ACS Chemical Biology
Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)
January 22, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics announces acceptance of BLA for obe-cel as a potential treatment for relapsed/refractory adult ALL
Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)
January 16, 2024 16:30 ET
|
Cellectis Inc.
NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors
January 10, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors
Monthly information on share capital and company voting rights
January 08, 2024 16:30 ET
|
Cellectis Inc.
PARIS, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
CARGO Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 08:05 ET
|
Cargo Therapeutics, Inc.
SAN MATEO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell...